Search Results
Your search for The ASCO ,The ASCO matches 21383 pages
Showing 51 - 100Outcomes of Oncologic Extended Resection for Gallbladder Cancer: Results of a Global Analysis
In the United States, approximately 55% of patients with resected gallbladder cancer undergo oncologic surgery without additional systemic treatment. However, as gallbladder cancer progresses to T3 (locally or regionally advanced) or T4 (distant metastasis) disease, the tumor frequently infiltrates ...
FDA Approves CD19-Directed Antibody–Based Regimen for Follicular Lymphoma
On June 18, the U.S. Food and Drug Administration approved tafasitamab-cxix (Monjuvi), a CD19-directed cytolytic antibody, with lenalidomide and rituximab for adults with relapsed or refractory follicular lymphoma. inMIND Trial Efficacy was evaluated in inMIND (ClinicalTrials.gov identifier...
Study Identifies Key LBCL Traits Tied to Greatest Benefit From CD19 CAR T-Cell Therapy
In the largest study of its kind, researchers from The University of Texas MD Anderson Cancer Center have identified three subgroups of patients with large B-cell lymphoma (LBCL) who have different levels of benefit from CD19-targeted chimeric antigen receptor (CAR) T cell therapy. In the study,...
Elevated Cardiac Biomarkers Associated With Increased Cancer Risk
Higher baseline levels of certain cardiac biomarkers were associated with an increased risk of future incidence of cancer, according to findings from a study published in the Journal of the American College of Cardiology: Advances. Higher incidence rates for all cancers were associated with higher ...
Psilocybin May Benefit Patients With Cancer, Major Depressive Disorder
A single dose of psilocybin may provide sustained reductions in depression and anxiety among patients with cancer and major depressive disorder, according to a recent study published by Agrawal et al in Cancer. Patients with cancer often experience depression. Psilocybin is a naturally occurring...
Order of CRC Diagnosis May Influence Survival in Patients With Multiple Malignancies
The order of colorectal cancer diagnosis seems to have a significant impact on outcomes in patients with multiple primary malignancies, according to the results of a study of Surveillance, Epidemiology, and End Results (SEER) Program data. Findings from the study were published in the Journal of...
Chronicling the Extraordinary Career of Stephen R. Grobmyer, MD, FACS, in Breast Cancer Research, Surgery, and Treatment
In this installment of The ASCO Post’s Living a Full Life series, Guest Editor Jame Abraham, MD, FACP, spoke with Stephen R. Grobmyer, MD, FACS, about his clinical and research career in oncology, the challenges and rewards of moving to Abu Dhabi and building a state-of-the-art cancer center, and...
BRCA Mutations Could Increase Risk of Rare Lymphoma Among Women Who Received Textured Breast Implants During Breast Cancer Treatment
The risk of developing breast implant–associated anaplastic large-cell lymphoma (ALCL) could be higher among women with breast cancer and BRCA1 or BRCA2 mutations who received textured breast implants as part of their postmastectomy reconstructive surgery compared with patients lacking the genetic...
Study Defines Divergent Molecular Pathways in HPV-Associated vs HPV-Independent Sinonasal Cancers
Findings from a comprehensive genome-wide study of sinonasal squamous cell carcinomas demonstrated that human papillomavirus (HPV) can drive tumorigenesis in some cases, and these tumors exhibit similar mutational patterns to those seen in HPV-associated cervical and head and neck squamous cell...
Revumenib in Triplet Regimen Under Study in Newly Diagnosed AML With NPM1/KMT2A Alterations
A new combination of azacitidine, venetoclax, and revumenib demonstrated high rates of complete response and clinical activity in older adults with newly diagnosed acute myeloid leukemia (AML) and an NPM1 mutation or KMT2A rearrangement. The regimen was also shown to be safe in updated results from ...
Early Results for CAR T-Cell Therapy in Relapsed or Refractory AL Amyloidosis
Initial early results were seen for the use of chimeric antigen receptor (CAR) T-cell therapy in patients with relapsed or refractory amyloid light-chain (AL) amyloidosis in the NEXICART-2 trial. This was the first U.S. trial of CAR T-cell therapy for patients with AL amyloidosis, demonstrating...
Erika Hamilton, MD, on ER-Positive HER2-Negative Advanced Breast Cancer: Vepdegestrant vs Fulvestrant
Erika Hamilton, MD, Director, Breast Cancer Research at Sarah Cannon Research Institute, reviews data from the global, randomized, phase III VERITAC-2 study, which compared vepdegestrant, an oral PROTAC (PROteolysis TArgeting Chimera) estrogen receptor degrader, to fulvestrant among patients with...
Gerhardt Attard, MD, PhD, on a Novel Regimen for Metastatic Castration-Sensitive Prostate Cancer With HRR Alterations
Gerhardt Attard, MD, PhD, of the Cancer Institute, University College London, presents findings from the phase III AMPLITUDE trial, which looked at the combination of niraparib and abiraterone acetate plus prednisone for patients with metastatic castration-sensitive prostate cancer with alterations ...
Colorectal Cancer Screening: CT Colonography vs Stool Testing
Computed tomography (CT) colonography demonstrated greater clinical efficacy and cost savings than stool DNA testing for colorectal cancer screening, according to results of a study published in Radiology. "Among the safe, minimally invasive colorectal cancer screening options, CT colonography is ...
FDA Approves Neoadjuvant and Adjuvant Pembrolizumab for Resectable, Locally Advanced Head and Neck Cancer
Yesterday, the U.S. Food and Drug Administration (FDA) approved pembrolizumab (Keytruda) for adults with resectable, locally advanced head and neck squamous cell carcinoma (HNSCC) whose tumors express PD-L1 [combined positive score (CPS) ≥ 1] as determined by an FDA-approved test, as a single agent ...
Could A Telehealth Program Enhance Geriatric Cancer Care?
A telehealth-based care program may improve daily functioning, mood, disease understanding, and quality of life among older adults with cancer, according to a recent study published by Bergerot et al in JNCCN–Journal of the National Comprehensive Cancer Network. Study Methods and Results...
Relacorilant and Nab-Paclitaxel in Platinum-Resistant Ovarian Cancer
In the phase III ROSELLA trial—reported at the 2025 ASCO Annual Meeting as well as in The Lancet—Olawaiye et al examined the survival benefit of adding relacorilant to nab-paclitaxel in women with platinum-resistant ovarian cancer. Relacorilant is a first-in-class selective glucocorticoid receptor...
FDA Approves Mitomycin Intravesical Solution for Recurrent Low-Grade Intermediate-Risk Non–Muscle-Invasive Bladder Cancer
On June 12, 2025, the U.S. Food and Drug Administration (FDA) approved mitomycin intravesical solution (Zusduri) for adult patients with recurrent low-grade intermediate-risk non–muscle-invasive bladder cancer. Mitomycin intravesical solution is a reverse thermal hydrogel formulation of mitomycin...
CancerCare Survey Reveals How Insurance Red Tape Impacts Cancer Treatment Delays
Findings from a first-of-its-kind national survey are included in “The Health Insurance Maze: How Cancer Patients Get Lost in the Red Tape of Utilization Management,” a new report from CancerCare which details the impact that prior authorization requirement and coverage stoppages have on patients...
Resectable NSCLC: Overall Survival With Neoadjuvant Nivolumab Plus Chemotherapy
In an analysis from the phase III CheckMate 816 trial reported at the 2025 ASCO Annual Meeting and in The New England Journal of Medicine, Forde et al examined overall survival outcomes with the addition of neoadjuvant nivolumab to platinum-based chemotherapy in patients with stage IB to IIIA...
Elinzanetant for Vasomotor Symptoms From Endocrine Therapy for Breast Cancer
In a phase III trial (OASIS-4) reported at the 2025 ASCO Annual Meeting and in The New England Journal of Medicine, Cardoso et al attempted to determine whether the neurokinin-targeted therapy elinzanetant reduced the risk of vasomotor symptoms from endocrine therapy for patients with hormone...
Nomogram Model May Predict DVT Risk in Patients With Ovarian Cancer
Researchers have developed a nomogram prediction model for the development of deep vein thrombosis (DVT) in patients with epithelial ovarian cancer, according to study results published in Menopause, the journal of The Menopause Society. A number of significant independent risk factors for DVT...
FDA Approves Taletrectinib for ROS1-Positive Non–Small Cell Lung Cancer
The U.S. Food and Drug Administration (FDA) has approved the oral next-generation ROS1 tyrosine kinase inhibitor (TKI) talectrectinib (Ibtrozi) for the treatment of adults with ROS1-positive locally advanced or metastatic non–small cell lung cancer (NSCLC). Investigators reported that the agent has ...
Study Reports Increasing Incidence Rates of Appendiceal Adenocarcinoma in Those Born After 1945
A recent study published in the Annals of Internal Medicine1 estimated incidence rates of appendiceal adenocarcinoma across birth cohorts in the United States. Andreana N. Holowatyj, PhD, MSCI, of Vanderbilt-Ingram Cancer Center, Nashville, and colleagues observed a sharp increase in incidence...
MRD-Guided Treatment in Newly Diagnosed Multiple Myeloma
In a French-Belgian phase III trial (MIDAS) reported at the 2025 ASCO Annual Meeting and in The New England Journal of Medicine, Perrot et al examined the outcomes of treatments guided by measurable residual disease (MRD) status in patients with newly diagnosed multiple myeloma. Study Details In...
Adjuvant Cemiplimab in High-Risk Cutaneous Squamous Cell Carcinoma
In a phase III trial (C-POST) reported at the 2025 ASCO Annual Meeting and in The New England Journal of Medicine, Rischin et al compared disease-free survival outcomes of adjuvant cemiplimab vs placebo in patients with high-risk cutaneous squamous cell carcinoma. Study Details In the trial, 415...
Self-Collection Kit Mailings May Increase Cervical Cancer Screening Rates in Underserved Settings
Mail-in self-collection kits for human papillomavirus (HPV) were found to be effective at increasing cervical cancer screening rates compared with standard telephone reminders alone in a safety-net health-care setting, according to results from the PRESTIS trial published in JAMA Internal Medicine. ...
Low-Value Cancer Screenings May Continue for Years Following Guideline Change to Limit Unnecessary Tests
Stopping the widespread use of unnecessary, potentially harmful cancer screenings may take up to 13 years and potentially longer following the implementation of new guidelines, according to a recent study published by LeLaurin et al in BMJ Quality & Safety. Background The U.S. Preventive...
AACR Statement on Former President Joseph Biden’s Cancer Diagnosis
The American Association for Cancer Research (AACR) has issued the following statement regarding former President Joseph R. Biden’s prostate cancer diagnosis: “The American Association for Cancer Research (AACR) offers heartfelt support and well wishes to former President Biden and his family as...
I Was an N-of-1 in a CAR T-Cell Therapy Trial for Ovarian Cancer
More than a decade after I was diagnosed with late-stage ovarian cancer, a phase I clinical trial at Moffitt Cancer Center and Research Institute in Tampa, Florida, investigating a dose of a novel follicle-stimulating hormone receptor (FSHR)-targeting chimeric antigen receptor (CAR) T-cell therapy...
MD Anderson Names Jeffrey E. Lee, MD, Chief Medical Executive
The University of Texas MD Anderson Cancer Center announced that Jeffrey E. Lee, MD, an internationally regarded leader in the field of oncology, has been appointed Chief Medical Executive (CME). Prior to his appointment, Dr. Lee served as CME ad interim. Assuming the role of CME is the...
Use of Bispecific Antibody in Older Patients With Relapsed or Refractory Multiple Myeloma
Although treatment with the bispecific antibody teclistamab was approved for patients with relapsed or refractory multiple myeloma, based on the MajesTEC-1 study results, only 15% of patients in the phase I/II trial were aged 75 or older. To learn more about the safety and efficacy of this agent in ...
ESTRO 2025: Major Advances in Radiotherapy for Anal and Rectal Cancers
In May in Vienna, five studies presented at ESTRO (European Society for Radiotherapy and Oncology) 2025 showcased how radiotherapy is reshaping the landscape for anal and rectal cancers. From reduced-dose treatments to cutting-edge combinations with immunotherapy and chemotherapy, these innovations ...
Why Black Women Have a Higher Risk of Dying of All Types of Breast Cancer Than White Women
The disparities in breast cancer incidence and mortality rates between Black and White women in the United States have been well documented. Studies over the past decade consistently show that although Black women have a 4% lower breast cancer incidence rate than White women, they are still between ...
ASTRO Survey Data Illustrate Impact of Continued Medicare Cuts on Cancer Care
Recent national survey data from the American Society for Radiation Oncology (ASTRO) have shown that further cuts to Medicare reimbursement for radiation therapy would increase patient wait times for cancer treatment and force clinic downsizing. Nearly all (96%) of the 675 physicians responding to...
Retifanlimab-dlwr Approved for Anal Cancer in Combination With Carboplatin Plus Paclitaxel and as a Single Agent
The U.S. Food and Drug Administration (FDA) approved retifanlimab-dlwr (Zynyz), a PD-1–blocking monoclonal antibody, with carboplatin and paclitaxel for the first-line treatment of adults with inoperable locally recurrent or metastatic squamous cell carcinoma of the anal canal. The FDA also...
Expanded Treatment Options for Metastatic CRPC: ASCO Guideline Addresses Somatic Genetic Testing, Radiopharmaceuticals
The management of metastatic (CRPC) has rapidly accelerated in the past decade, giving oncologists a wider range of tools to work with and patients new opportunities for improving survival and maintaining quality of life. These significant advancements have prompted ASCO to release a guideline...
How the Elimination of Federal Gender-Related Grants and DEI Programs Is Impacting LGBTQ+ Health Research
Within hours of the start of his second administration, on January 20, 2025, President Donald Trump signed an executive order proclaiming that the country would now recognize only two sexes, male and female, essentially rejecting transgender identity, and directing all federal agencies to use the...
Improving the Alliance Between Oncologists and Primary Care Providers: A Call for Collaborative Action
Experts and patients alike would agree that navigating the current fragmented U.S. health-care system is not an easy task. One component of that disconnection may center on the relationship between oncology and primary care. The benefits of collaboration between oncologists and primary care...
Study Shows Potential Benefits of AI-Assisted Classification in HER2-Low and HER2-Ultralow Breast Cancer
With the approval of HER2-targeted antibody-drug conjugate options for treating patients with breast cancer across different HER2 expression levels, accurate assessment of HER2 expression has become more important than ever. And a recent study may provide a solution to the challenge of accurate...
Structured Exercise Program Improves Survival Outcomes in Patients With Stage III or High-Risk Stage II Colon Cancer
A 3-year structured exercise program initiated soon after completion of adjuvant chemotherapy improved disease-free survival and overall survival, as well as patient-reported physical functioning and health-related fitness, in patients with stage III or high-risk stage II colon cancer. These...
Study Finds GLP-1RAs May Lower Risk of Obesity-Related Cancers vs DPP-4 Inhibitors in Adults With Diabetes and Obesity
Studies have shown that being overweight or having obesity increases the risk of developing more than a dozen cancers, including meningioma, multiple myeloma, esophageal, thyroid, breast, gallbladder, stomach, liver, pancreas, kidney, ovarian, uterus, and colorectal.1 The presence of excess body...
Maintenance Therapy With Lurbinectedin Plus Atezolizumab Improves Survival Outcomes in Extensive-Stage Small Cell Lung Cancer
Maintenance treatment with the alkylating agent lurbinectedin plus the monoclonal antibody atezolizumab significantly improved both progression-free survival and overall survival compared with atezolizumab alone in patients with extensive-stage small cell lung cancer (SCLC), according to data...
Overall Survival Benefit Achieved With Inavolisib Plus Palbociclib and Fulvestrant in Advanced Breast Cancer
“Inavolisib plus palbociclib and fulvestrant significantly improved overall survival compared with placebo plus palbociclib/fulvestrant…. This is the first time overall survival has been significantly improved by a PI3K pathway–targeted drug,” said Nicholas Turner, MD, PhD, FRCP,FMedSci, who...
Inherited Genetic Differences May Predict Resistance to Immunotherapy in Metastatic Melanoma
Researchers may have uncovered genetic differences that may help predict response to immune checkpoint inhibitors among patients with metastatic melanoma, according to a recent study published by Monson et al in Nature Medicine. Background The investigation revolved around mitochondrial haplogroups ...
Use of Adjuvant Aspirin Reduces the Risk of Recurrence in PI3K-Mutated Colorectal Cancer
In the phase III ALASCCA trial, the use of adjuvant daily aspirin for 3 years reduced the risk of recurrence in colorectal cancer harboring PI3K pathway alterations by 51%, according to research in a Scandinavian population presented at the 2025 ASCO Gastrointestinal Cancers Symposium by Anna...
Cancer May Be Detectable in Bloodstream 3 Years Prior to Diagnosis
Genetic material shed by tumors may be detected in the bloodstream 3 years prior to cancer diagnosis, according to a recent study published by Wang et al in Cancer Discovery. Study Methods and Results Researchers used highly accurate and sensitive sequencing techniques to analyze the plasma samples ...
Ruben A. Mesa, MD, on Essential Thrombocythemia: SURPASS-ET Trial
Ruben A. Mesa, MD, of Atrium Health Wake Forest Baptist Comprehensive Cancer Center, Wake Forest University School of Medicine, presents results from a phase III trial investigating the efficacy of ropeginterferon alfa-2b vs anagrelide for the treatment of essential thrombocythemia (Abstract 6500). ...
Violaine Randrian, MD, PhD, on Lynch Syndrome, Genetics, and Immunotherapy
Violaine Randrian, MD, PhD, of Memorial Sloan Kettering Cancer Center and CHU/Université de Poitiers, reviews gene-specific outcomes in patients with Lynch syndrome treated with immune checkpoint inhibitors for advanced cancer (Abstract 10504).
ACS CAN Statement on Federal Cuts to Cancer Research
On May 30, President Donald Trump released his final proposed budget for Fiscal Year 2026, which contains $4.531 billion for the National Cancer Institute (NCI). This represents a cut of almost $2.7 billion, or approximately 37.2%, from the current fiscal year. The following is a statement from...
